Comparison of acamprosate and placebo in long-term treatment of alcohol dependence

Lancet

Volumn 347, Issue 9013, 1996, Pages 1438-1442

  Whitworth, Alexandra B ^a   Fischer, Felix ^e   Lesch, Otto M ^b   Nimmerrichter, Amanda ^c   Oberbauer, Harald ^a   Platz, Thomas ^d   Potgieter, Adriaan ^f   Walter, Henriette ^b   Fleischhacker, W Wolfgang ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c Anton Proksch Institute   (Austria)

^d GENERAL HOSPITAL KLAGENFURT   (Austria)

^e Genesungsheim Landes Oberoesterreich   (Austria)

^f Groupe Lipha   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE;

ADULT; ALCOHOL ABSTINENCE; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0029994413     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)91682-7     Document Type: Article

References (29)

1. Miller WR, Hester RK. The effectiveness of alcoholism treatment methods: what research reveals. In: Miller WR, Heather N, eds. Treating addictive behaviors: process of change. New York: Plenum Press, 1986: 121-74.
2. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatr 1992; 49: 876-80.
3. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. Arch Gen Psychiatry 1992; 49: 881-87.
4. Mason BJ, Ritvo EC, Morgan RO, et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCL for alcohol dependence. Alcohol Clin Exp Res 1994; 18: 1162-67.
5. Naranjo CA, Kadlec KE. Possible pharmacological probes for predicting and preventing relapse in treated alcoholics. Alcohol-Alcohol Suppl 1991; 1: 523-26.
6. 3 antagonist ondansetron in alcohol abuse and dependence. Alcoholism Clin Exp Res 1994; 18: 879-85.
7. Shaw GK, Waller S, Majumdar SK, Alberts JL, Latham CJ, Dunn G. Tiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry 1994; 165: 515-23.
8. Borg V. Bromocriptine in the prevention of alcohol abuse. Acta Psychiatr Scand 1983; 68: 100-10.
9. Gallimberti L, Ferri M, Ferrara SD, Fadda F, Gessa GL. Gamma-hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study. Alcohol Clin Exp Res 1992; 16: 673-76.
10. Boismare F, Daoust M, Moore ND, et al. A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? Pharmacol Biochem Behav 1984; 21: 787-89.
11. Daoust M, Legrand E, Gewiss M, et al. Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised rats. Pharmacol Biochem Behav 1992; 41: 669-74.
12. Zeise ML, Kasparov S, Capogna M, Zieglgänsberger W. Acamprosate (calcium acetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. Eur J Pharmacol 1993; 231: 47-52.
13. Rassnick S, D'Amoco L, Riley E, Pulvirenti L, Zieglgänsberger W, Koob GF. GABA and nucleus accumbens glutamate neuro transmission modulate ethanol self-administration in rats. Ann NY Acad Sci 992; 654: 502.
14. Le Magnen J, Tran G, Durlach J, Martin C. Dose-dependent suppression of the alcohol intake on chronically intoxicated rats by Ca-acetyl homotaurinate. Alcohol 1987; 4: 97-102.
15. Grant KA, Woolverton WL. Reinforcing and discriminative stimulus effects of Ca-acetyl homotaurine in animals. Pharmacol Biochem Behav 1989; 32: 606-11.
16. Lhuintre J, Daoust M, Moore N, et al. Ability of calcium bis acetyl homotaurine, a GABA agonist to prevent relapse in weaned alcoholics. Lancet 1985; i: 1014-16.
17. Lhuintre JP, Moore N, Tran G, et al. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcoholism 1990; 25: 613-22.
18. Gerra G, Caccavari R, Delsignore R, Bocchi R, Fertonani G, Passeri M. Effects of fluoxetine and CA-acetyl-homotaurinate on alcohol intake in familial and non-familial alcoholic patients. Curr Ther Res 1992; 52: 291-95.
19. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcoholism 1995; 30: 239-47.
20. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, DSM-III, 3rd ed. Washington, DC: American Psychiatric Association, 1980: 163-70.
21. Ewing JA. Detecting alcoholism: the CAGE questionnaire. JAMA 1984; 252: 1905-07.
22. Selzer ML. The Michigan alcoholism screening test: the quest for a new diagnostic instrument. Am J Pschiatry 1971; 127: 1653-58.
23. Lehert P. Review and discussion of the statistical analysis of controlled trials in alcoholism. Alcohol-Alcohol Suppl 1993; 2: 157-63.
24. Hamilton M. A rating scale for depression. J Neurol Neurosurg Pschiatry 1960; 23: 56-62.
25. Kranzler HR, Burleson JA, Korner P, et al. Placebo-controlled trial of fluoxetine in an adjunct to relapse prevention in alcoholics. Am J Psychiatry 1995; 152: 391-97.
26. Greb J. A trial of ritanserin in patients with alcohol abuse. Paper presented at the NCDEU 1995, Orlando, Florida (in press).
27. Fawcett J, Clark DC, Aagesen CA, et al. A double-blind, placebo-controlled trial of lithium carbonate therapy for alcoholism. Arch Gen Psychiatry 1987; 44: 248-56.
28. Crofton J. Extent and costs of alcohol problems in employment: a review of British data. Alcohol Alcoholism 1987; 22: 321-25.
29. Burke TR. The economic impact of alcohol abuse and alcoholism. Public Health Rep 1988; 6: 564-68.